Type 2 diabetes care plans in Australia: the four MBS items most GPs leave on the table

Around 1.3 million Australians have Type 2 diabetes. Roughly 80% are managed primarily in general practice. The Medicare system funds chronic disease care for them more generously than for any other condition — and yet the average practice claims about 45% of what's available.

The four items the Annual Cycle of Care unlocks

• MBS 721 — initial GPMP, $164.35. Done once.
• MBS 732 — review of the management plan, $82.20. Twice per year.
• MBS 723 — Team Care Arrangement, $130.25. Once per plan, unlocks 5 allied-health visits.
• MBS 66719 — HbA1c pathology, $19.65. Up to four per year, claimed under the cycle of care.

Add it up: $164 + ($82 × 2) + $130 + ($19 × 4) = $534, plus the standard consults around them. Realistically, an actively managed T2DM patient generates $680–$740 per year in Medicare claims when the cycle is followed properly. Most practices claim less than half of that.

Where it falls apart

The 723 TCA is the most-missed. A GPMP without a 723 means no subsidised dietitian, no diabetes educator referral, no podiatry. The patient gets the plan but not the team behind it. Five allied-health visits per calendar year are forfeited for every TCA that doesn't get drafted alongside the 721.

The 66719 pathology item is the second-most-missed. The blood test gets ordered — but under generic consult coding, not the Annual Cycle of Care item that triggers the higher rebate.

The clinical case underneath the revenue case

Patients on an actively managed cycle of care have measurably better outcomes. RACGP data: cycle-of-care patients hit HbA1c targets 38% more often than non-cycle patients. They have 24% fewer emergency presentations. They live longer. The Medicare structure exists because the medicine actually works.